Press Releases Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
9.5 ^CHF	0.00%		+4.28%	-3.16%

Apr. 25	Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024
Apr. 25	Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May	Apr. 25	AQ
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA	Mar. 27	AQ
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States	Mar. 14	AQ
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology	Feb. 14	AQ
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	Jan. 15	AQ
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom	Jan. 12	AQ
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy	Dec. 18	AQ
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage	Dec. 07	AQ
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals	23-10-27	AQ
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy	23-10-27	AQ
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy	23-10-13	AQ
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update	23-09-07	AQ
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group	23-07-31	AQ
Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone	23-07-19	AQ
Santhera Publishes Timeline of the Reverse Share Split	23-06-29	GL
Santhera Publishes Timeline of the Reverse Share Split	23-06-29	AQ
Shareholders Approve all Board Proposals at Today’s Annual General Meeting	23-06-27	GL
Shareholders Approve all Board Proposals at Today’s Annual General Meeting	23-06-27	AQ
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals	23-06-20	AQ
Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties	23-06-20	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Press Releases

Filters